A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07888075

Title field or adapter rule

{'original_value': 'A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:28.880328+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-10-31T22:18:26.854673+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Cachexia; Cancer", "Cachexia", "Cachexia-Anorexia Syndrome", "Metastatic Colorectal Cancer (CRC)", "Metastatic Non-small Cell Lung Cancer (NSCLC)", "Weight Loss", "Anorexia"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07888075"

protocolSection.identificationModule.officialTitle

"A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2", "PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Cachexia; Cancer (protocolSection.conditionsModule.conditions)
• Cachexia (protocolSection.conditionsModule.conditions)
• Cachexia-Anorexia Syndrome (protocolSection.conditionsModule.conditions)
• Metastatic Colorectal Cancer (CRC) (protocolSection.conditionsModule.conditions)
• Metastatic Non-small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
• Weight Loss (protocolSection.conditionsModule.conditions)
• Anorexia (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Rilogrotug - high dose', 'Rilogrotug - low dose'], 'description': 'Rilogrotug (AV-380) is a humanized immunoglobulin G1 kappa monoclonal antibody that binds to growth differentiation factor-15 (GDF-15).', 'name': 'Rilogrotug', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Placebo'], 'description': 'Placebo for this study will be normal saline.', 'name': 'Placebo', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.